Neutrophil-activating Peptide 2 as a Novel modulator of fibrin clot properties in patients with atrial fibrillation

2024
journal article
article
2
dc.abstract.enNeutrophil-activating peptide2 (NAP-2, CXCL7), a platelet-derived neutrophil chemoattractant, is involved in inflammation. We investigated associations between NAP-2 levels, neutrophil extracellular traps (NETs) formation, and fibrin clot properties in atrial fibrillation (AF). We recruited 237 consecutive patients with AF (mean age, 68 ± 11 years; median CHA2DS2VASc score of 3 [2–4]) and 30 apparently healthy controls. Plasma NAP-2 concentrations were measured, along with plasma fibrin clot permeability (Ks) and clot lysis time (CLT), thrombin generation, citrullinated histone H3 (citH3), as a marker of NETs formation, and 3-nitrotyrosine reflecting oxidative stress. NAP-2 levels were 89% higher in AF patients than in controls (626 [448–796] vs. 331 [226–430] ng/ml; p < 0.0001). NAP-2 levels were not associated with demographics, CHA2DS2- VASc score, or the AF manifestation. Patients with NAP-2 in the top quartile (> 796 ng/ml) were characterized by higher neutrophil count (+ 31.7%), fibrinogen (+ 20.8%), citH3 (+ 86%), and 3-nitrotyrosine (+ 111%) levels, along with 20.2% reduced Ks and 8.4% prolonged CLT as compared to the remaining subjects (all p < 0.05). NAP-2 levels were positively associated with fibrinogen in AF patients (r = 0.41, p = 0.0006) and controls (r = 0.65, p < 0.01), along with citH3 (r = 0.36, p < 0.0001) and 3-nitrotyrosine (r = 0.51, p < 0.0001) in the former group. After adjustment for fibrinogen, higher citH3 (per 1 ng/ml β = -0.046, 95% CI -0.029; -0.064) and NAP-2 (per 100 ng/ml β = -0.21, 95% CI -0.14; -0.28) levels were independently associated with reduced Ks. Elevated NAP-2, associated with increased oxidative stress, has been identified as a novel modulator of prothrombotic plasma fibrin clot properties in patients with AF.
dc.affiliationPion Prorektora ds. Collegium Medicum : Centrum Innowacyjnej Edukacji Medycznej CMpl
dc.affiliationWydział Lekarski : Instytut Kardiologiipl
dc.cm.date2023-06-28T22:17:35Z
dc.cm.id112347pl
dc.cm.idOmegaUJCM7b30cc5a403d470d8e8c913b227ec64fpl
dc.contributor.authorZąbczyk, Michał - 137370 pl
dc.contributor.authorNatorska, Joanna - 130892 pl
dc.contributor.authorMatusik, Paweł - 139227 pl
dc.contributor.authorMołek, Patrycjapl
dc.contributor.authorWojciechowska, Wiktoria - 354804 pl
dc.contributor.authorRajzer, Marek - 133260 pl
dc.contributor.authorRajtar-Salwa, Renatapl
dc.contributor.authorTokarek, Tomasz - 162633 pl
dc.contributor.authorLenart-Migdalska, Aleksandrapl
dc.contributor.authorOlszowska, Maria - 133035 pl
dc.contributor.authorUndas, Anetta - 133708 pl
dc.date.accession2023-06-12pl
dc.date.accessioned2023-06-28T22:17:35Z
dc.date.available2023-06-28T22:17:35Z
dc.date.issued2024
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.additionalOnline First 2023-06-09pl
dc.description.number4
dc.description.physical773-783
dc.description.versionostateczna wersja wydawcy
dc.description.volume15
dc.identifier.doi10.1007/s12975-023-01165-1pl
dc.identifier.eissn1868-601Xpl
dc.identifier.issn1868-4483pl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/313121
dc.identifier.weblinkhttps://doi.org/10.1007/s12975-023-01165-1pl
dc.languageengpl
dc.language.containerengpl
dc.pbn.affiliationDziedzina nauk medycznych i nauk o zdrowiu : nauki medyczne
dc.rightsUdzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa
dc.rights.licenceCC-BY
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/legalcode.pl
dc.share.typeOtwarte czasopismo
dc.subject.enatrial fibrillation
dc.subject.enfibrin clot
dc.subject.enneutrophil-activating peptide 2
dc.subject.enoxidative stress
dc.subtypeArticlepl
dc.titleNeutrophil-activating Peptide 2 as a Novel modulator of fibrin clot properties in patients with atrial fibrillationpl
dc.title.journalTranslational Stroke Researchpl
dc.typeJournalArticlepl
dspace.entity.typePublication
dc.abstract.en
Neutrophil-activating peptide2 (NAP-2, CXCL7), a platelet-derived neutrophil chemoattractant, is involved in inflammation. We investigated associations between NAP-2 levels, neutrophil extracellular traps (NETs) formation, and fibrin clot properties in atrial fibrillation (AF). We recruited 237 consecutive patients with AF (mean age, 68 ± 11 years; median CHA2DS2VASc score of 3 [2–4]) and 30 apparently healthy controls. Plasma NAP-2 concentrations were measured, along with plasma fibrin clot permeability (Ks) and clot lysis time (CLT), thrombin generation, citrullinated histone H3 (citH3), as a marker of NETs formation, and 3-nitrotyrosine reflecting oxidative stress. NAP-2 levels were 89% higher in AF patients than in controls (626 [448–796] vs. 331 [226–430] ng/ml; p < 0.0001). NAP-2 levels were not associated with demographics, CHA2DS2- VASc score, or the AF manifestation. Patients with NAP-2 in the top quartile (> 796 ng/ml) were characterized by higher neutrophil count (+ 31.7%), fibrinogen (+ 20.8%), citH3 (+ 86%), and 3-nitrotyrosine (+ 111%) levels, along with 20.2% reduced Ks and 8.4% prolonged CLT as compared to the remaining subjects (all p < 0.05). NAP-2 levels were positively associated with fibrinogen in AF patients (r = 0.41, p = 0.0006) and controls (r = 0.65, p < 0.01), along with citH3 (r = 0.36, p < 0.0001) and 3-nitrotyrosine (r = 0.51, p < 0.0001) in the former group. After adjustment for fibrinogen, higher citH3 (per 1 ng/ml β = -0.046, 95% CI -0.029; -0.064) and NAP-2 (per 100 ng/ml β = -0.21, 95% CI -0.14; -0.28) levels were independently associated with reduced Ks. Elevated NAP-2, associated with increased oxidative stress, has been identified as a novel modulator of prothrombotic plasma fibrin clot properties in patients with AF.
dc.affiliationpl
Pion Prorektora ds. Collegium Medicum : Centrum Innowacyjnej Edukacji Medycznej CM
dc.affiliationpl
Wydział Lekarski : Instytut Kardiologii
dc.cm.date
2023-06-28T22:17:35Z
dc.cm.idpl
112347
dc.cm.idOmegapl
UJCM7b30cc5a403d470d8e8c913b227ec64f
dc.contributor.authorpl
Ząbczyk, Michał - 137370
dc.contributor.authorpl
Natorska, Joanna - 130892
dc.contributor.authorpl
Matusik, Paweł - 139227
dc.contributor.authorpl
Mołek, Patrycja
dc.contributor.authorpl
Wojciechowska, Wiktoria - 354804
dc.contributor.authorpl
Rajzer, Marek - 133260
dc.contributor.authorpl
Rajtar-Salwa, Renata
dc.contributor.authorpl
Tokarek, Tomasz - 162633
dc.contributor.authorpl
Lenart-Migdalska, Aleksandra
dc.contributor.authorpl
Olszowska, Maria - 133035
dc.contributor.authorpl
Undas, Anetta - 133708
dc.date.accessionpl
2023-06-12
dc.date.accessioned
2023-06-28T22:17:35Z
dc.date.available
2023-06-28T22:17:35Z
dc.date.issued
2024
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.additionalpl
Online First 2023-06-09
dc.description.number
4
dc.description.physical
773-783
dc.description.version
ostateczna wersja wydawcy
dc.description.volume
15
dc.identifier.doipl
10.1007/s12975-023-01165-1
dc.identifier.eissnpl
1868-601X
dc.identifier.issnpl
1868-4483
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/313121
dc.identifier.weblinkpl
https://doi.org/10.1007/s12975-023-01165-1
dc.languagepl
eng
dc.language.containerpl
eng
dc.pbn.affiliation
Dziedzina nauk medycznych i nauk o zdrowiu : nauki medyczne
dc.rights
Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa
dc.rights.licence
CC-BY
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/legalcode.pl
dc.share.type
Otwarte czasopismo
dc.subject.en
atrial fibrillation
dc.subject.en
fibrin clot
dc.subject.en
neutrophil-activating peptide 2
dc.subject.en
oxidative stress
dc.subtypepl
Article
dc.titlepl
Neutrophil-activating Peptide 2 as a Novel modulator of fibrin clot properties in patients with atrial fibrillation
dc.title.journalpl
Translational Stroke Research
dc.typepl
JournalArticle
dspace.entity.type
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
18
Views per month
Views per city
Krakow
8
Warsaw
7
Hong Kong
2
Downloads
zabczyk_et-al_neutrophil-activating_peptide_2024.pdf
2